JP2018148931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018148931A5 JP2018148931A5 JP2018124311A JP2018124311A JP2018148931A5 JP 2018148931 A5 JP2018148931 A5 JP 2018148931A5 JP 2018124311 A JP2018124311 A JP 2018124311A JP 2018124311 A JP2018124311 A JP 2018124311A JP 2018148931 A5 JP2018148931 A5 JP 2018148931A5
- Authority
- JP
- Japan
- Prior art keywords
- variants
- locus
- dcr3
- subject
- comprises seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims 17
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims 17
- 238000000034 method Methods 0.000 claims 9
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 5
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 4
- 238000003205 genotyping method Methods 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824932P | 2013-05-17 | 2013-05-17 | |
| US61/824,932 | 2013-05-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514143A Division JP6482533B2 (ja) | 2013-05-17 | 2014-05-16 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096798A Division JP2020127437A (ja) | 2013-05-17 | 2020-06-03 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018148931A JP2018148931A (ja) | 2018-09-27 |
| JP2018148931A5 true JP2018148931A5 (enExample) | 2019-03-14 |
Family
ID=51899024
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514143A Active JP6482533B2 (ja) | 2013-05-17 | 2014-05-16 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2018124311A Withdrawn JP2018148931A (ja) | 2013-05-17 | 2018-06-29 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2020096798A Withdrawn JP2020127437A (ja) | 2013-05-17 | 2020-06-03 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2022093628A Withdrawn JP2022111329A (ja) | 2013-05-17 | 2022-06-09 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2024213907A Pending JP2025023316A (ja) | 2013-05-17 | 2024-12-06 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514143A Active JP6482533B2 (ja) | 2013-05-17 | 2014-05-16 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096798A Withdrawn JP2020127437A (ja) | 2013-05-17 | 2020-06-03 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2022093628A Withdrawn JP2022111329A (ja) | 2013-05-17 | 2022-06-09 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2024213907A Pending JP2025023316A (ja) | 2013-05-17 | 2024-12-06 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20160090629A1 (enExample) |
| EP (3) | EP3498867B1 (enExample) |
| JP (5) | JP6482533B2 (enExample) |
| KR (4) | KR102295125B1 (enExample) |
| CN (1) | CN105358713B (enExample) |
| ES (1) | ES2894963T3 (enExample) |
| WO (1) | WO2014186750A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| BR112014007426B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| KR102295125B1 (ko) | 2013-05-17 | 2021-08-31 | 세다르스-신나이 메디칼 센터 | 크론병과 연관된 tnfsf15와 dcr3의 변이체 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| EP3337509A4 (en) | 2015-08-21 | 2019-01-02 | The Children's Hospital of Philadelphia | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| KR102481305B1 (ko) * | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| CA3111819A1 (en) * | 2018-09-07 | 2020-03-12 | The Children's Hospital Of Philadelphia | Compositions and methods for the diagnosis and treatment of lymphatic system disorders |
| WO2020232125A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
| AU2020346580A1 (en) * | 2019-09-13 | 2022-03-31 | Kyowa Kirin Co., Ltd. | DcR3 variant |
| WO2022103961A1 (en) * | 2020-11-13 | 2022-05-19 | Prometheus Biosciences, Inc. | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
| WO2008106451A2 (en) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2009052512A2 (en) | 2007-10-19 | 2009-04-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| AU2009215441B2 (en) * | 2008-02-19 | 2015-07-02 | The Children's Hospital Of Philadelphia | Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same |
| WO2010118210A1 (en) * | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| CA2758531C (en) * | 2009-04-14 | 2018-11-13 | Derren Barken | Inflammatory bowel disease prognostics |
| AU2011317149B2 (en) | 2010-10-18 | 2015-05-07 | Société des Produits Nestlé S.A. | Methods for determining anti-drug antibody isotypes |
| ES2530175T3 (es) | 2011-02-17 | 2015-02-26 | Nestec S.A. | Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF |
| WO2012161856A1 (en) | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| US20140170157A1 (en) | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| EP2565277A1 (en) | 2011-09-05 | 2013-03-06 | Progenika Biopharma, S.A. | Method for predicting radiographic severity in ankylosing spondylitis |
| SG11201401536QA (en) | 2011-10-21 | 2014-05-29 | Nestec Sa | Methods for improving inflammatory bowel disease diagnosis |
| KR102295125B1 (ko) | 2013-05-17 | 2021-08-31 | 세다르스-신나이 메디칼 센터 | 크론병과 연관된 tnfsf15와 dcr3의 변이체 |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
-
2014
- 2014-05-16 KR KR1020157034355A patent/KR102295125B1/ko active Active
- 2014-05-16 US US14/890,712 patent/US20160090629A1/en not_active Abandoned
- 2014-05-16 KR KR1020237020524A patent/KR20230093538A/ko not_active Ceased
- 2014-05-16 CN CN201480038133.6A patent/CN105358713B/zh active Active
- 2014-05-16 EP EP18201967.9A patent/EP3498867B1/en active Active
- 2014-05-16 KR KR1020257028341A patent/KR20250130857A/ko active Pending
- 2014-05-16 WO PCT/US2014/038468 patent/WO2014186750A2/en not_active Ceased
- 2014-05-16 ES ES18201967T patent/ES2894963T3/es active Active
- 2014-05-16 EP EP21193676.0A patent/EP3988673A3/en active Pending
- 2014-05-16 JP JP2016514143A patent/JP6482533B2/ja active Active
- 2014-05-16 EP EP14797214.5A patent/EP2997165A4/en not_active Withdrawn
- 2014-05-16 KR KR1020217026836A patent/KR20210107176A/ko not_active Ceased
-
2018
- 2018-04-05 US US15/946,632 patent/US20180230543A1/en not_active Abandoned
- 2018-06-29 JP JP2018124311A patent/JP2018148931A/ja not_active Withdrawn
-
2020
- 2020-06-03 JP JP2020096798A patent/JP2020127437A/ja not_active Withdrawn
-
2021
- 2021-08-02 US US17/392,098 patent/US12281359B2/en active Active
-
2022
- 2022-06-09 JP JP2022093628A patent/JP2022111329A/ja not_active Withdrawn
-
2024
- 2024-12-06 JP JP2024213907A patent/JP2025023316A/ja active Pending
-
2025
- 2025-03-19 US US19/084,586 patent/US20250243548A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018148931A5 (enExample) | ||
| JP2020127437A5 (enExample) | ||
| Sutton et al. | Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia | |
| Bang et al. | Comorbidities and metabolic derangement of NAFLD | |
| JP2014239695A5 (enExample) | ||
| JP2016198116A5 (enExample) | ||
| JP2016526875A5 (enExample) | ||
| JP2018519508A5 (enExample) | ||
| JP2016169229A5 (enExample) | ||
| Kong et al. | Detection methods of cyprinid herpesvirus 2 infection in silver crucian carp (Carassius auratus gibelio) via a pORF 72 monoclonal antibody | |
| JP2016512214A5 (enExample) | ||
| JP2018507254A5 (enExample) | ||
| JP2018531892A5 (enExample) | ||
| JP2014502848A5 (enExample) | ||
| Gutjahr et al. | Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects | |
| JP2018504903A5 (enExample) | ||
| Morè et al. | Current main topics in multiple myeloma | |
| Verma et al. | Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in mice | |
| JP2019516104A5 (enExample) | ||
| Gorsane et al. | Post kidney transplantation Kaposi's sarcoma: the experience of a Mediterranean North African center | |
| JP2019513346A5 (enExample) | ||
| WO2018075633A3 (en) | Compositions and methods for detecting or quantifying hepatitis c virus | |
| Imsonpang et al. | Confirmatory test of active IHHNV infection in shrimp by immunohistochemistry and IHHNV‐LongAmp PCR | |
| JP2018520366A5 (enExample) | ||
| JP4898434B2 (ja) | Ｂ型肝炎ウィルスの新規の表面タンパク質（ＨＢｓＡｇ）変異体 |